Product Images Sildenafil

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 21 images provide visual information about the product associated with Sildenafil NDC 0591-4050 by Actavis Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

fig1 - image 1

fig9 - image 10

fig10 - image 11

This appears to be a medical study evaluating the effectiveness of Sildenafil (20 mg TID) in treating patients with pulmonary arterial hypertension (PAH) based on their baseline walk distance and functional capacity. The study compared the results of patients who were given Sildenafil versus a placebo and measured their 6-minute walking distance post-treatment. The text provides a table with various measurements including ages, PAP, and PVRI values. The chart also shows a graph with placebo-corrected changes in 6-minute walking distances (in meters) for the groups.*

fig11 - image 12

fig12 - image 13

This text appears to be a graph showing the mean change from baseline for different treatments at different weeks of a study up to week 12. It is not possible to discern the exact details without the visual aid of the graph.*

ifu-fig-a - image 14

ifu-fig-b - image 15

ifu-fig-c - image 16

ifu-fig-d - image 17

ifu-fig-e - image 18

ifu-fig-f - image 19

fig2 - image 2

ifu-fig-g - image 20

prf 4 PDP - image 21

This is a medication label for Sildenafil - Sildenafil oral suspension. The recommended storage temperature before reconstitution is below 30°C/86°F. After reconstitution, it should be stored either below 30°C/86°F or in a refrigerator at 2-8°C (36-46°F). The suspension contains 10mg of Sildenafil per 3mL and comes in a grape flavor. The recommended dosage should be prescribed by a doctor. The label provides instructions on how to reconstitute the suspension using water, and warns to discard any unused portions after the recommended 60 days of use. The manufacturer is listed as To Pramcentss SA, and the product is for oral use only.*

fig3 - image 3

fig4 - image 4

fig5 - image 5

fig6 - image 6

This appears to be a table showing estimated cumulative mortality rates (%) for individuals exposed to different doses of a certain substance over time. There are three different dose levels: high, medium, and low. The table shows the mortality rates for each dosage level over a period of five years.*

formula - image 7

fig7 - image 8

The table provides recommendations for drug-dose adjustments for interacting medications. The drugs listed, such as Atorvastatin and Oral Contraceptives, do not require adjustments for dosages. However, drugs like Ritonavir are not recommended to be co-administered, as it can cause side effects. In addition, the last line indicates that adding sildenafil to bosentan therapy does not lead to any benefits for exercise capacity.*

fig8 - image 9

This is a list of drugs and their respective recommendation for dose adjustment when interacting with other drugs. Most of the drugs require no adjustment except for Ritonavir, which is not recommended for co-administration. The text also contains a chart showing the change relative to the interacting drug alone that ranges from 0.5 to 2.0. There is a note about the benefit of adding sildenafil to bosentan therapy for exercise capacity, and the effect of ritonavir on sildenafil PK.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents